首页> 外文期刊>Health technology assessment: HTA >Cyclooxygenase-2 selective non-steroidal anti-inflammatory (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis or rheumatoid arthritis: a systematic review and economic evaluation

【24h】

Cyclooxygenase-2 selective non-steroidal anti-inflammatory (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis or rheumatoid arthritis: a systematic review and economic evaluation

机译：环氧合酶2选择性非甾体类抗炎药（依托度酸，美洛昔康，塞来考昔，罗非考昔，依托考昔，伐地考昔和鲁美昔布）用于骨关节炎或类风湿关节炎的系统评价和经济评价

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Health technology assessment: HTA》 |2008年第11期|共页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类放射卫生;
关键词
入库时间 2022-08-18 15:31:21

相似文献

外文文献
中文文献
专利

1. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. [J] . Chen YF, Jobanputra P, Barton P, Health technology assessment: HTA . 2008,第11期

机译：环氧合酶2选择性非甾体类抗炎药（依托度酸，美洛昔康，塞来考昔，罗非考昔，依托考昔，伐地考昔和鲁美昔布）用于骨关节炎和类风湿关节炎的系统评价和经济评价。
2. Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide. [J] . Inomata N, Osuna H, Yamaguchi J, The Journal of dermatology . 2007,第3期

机译：在患有NSAID引起的荨麻疹和/或血管性水肿的日本患者中，选择性环氧合酶2抑制剂和基本的非甾体类抗炎药（NSAID）的安全性：美洛昔康，依托度酸和tiaramide的比较。
3. Anti-inflammatory effect and low ulcerogenic activity of etodolac, a cyclooxygenase-2 selective non-steroidal anti-inflammatory drug, on adjuvant-induced arthritis in rats. [J] . Tachibana M, Inoue N, Yoshida E, Pharmacology: International Journal of Experimental and Clinical Pharmacology . 2003,第2期

机译：依托度酸（一种环氧合酶2选择性非甾体类抗炎药）对佐剂诱导的大鼠关节炎具有抗炎作用，且其低溃疡活性。
4. Selective cyclooxygenase-2 (COX-2) inhibition and risk of acute myocardial infarction or stroke in a population of rheumatoid arthritis and osteoarthritis patients from an administrative medical claims dataset. [D] . Spalding, William Michael. 2003

机译：来自行政医疗索赔数据集的类风湿关节炎和骨关节炎患者群体中的选择性环氧合酶2（COX-2）抑制和急性心肌梗塞或中风的风险。
5. Evaluation of two doses of etoricoxib a COX-2 selective non-steroidal anti-inflammatory drug (NSAID) in the treatment of Rheumatoid Arthritis in a double-blind randomized controlled trial [O] . Kara Bickham, Alan J. Kivitz, Anish Mehta, 2016

机译：在双盲随机对照试验中评估两种剂量的依托考昔一种COX-2选择性非甾体类抗炎药（NSAID）用于治疗类风湿关节炎
6. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation [O] . Y Chen, P Jobanputra, P Barton, 2008

机译：环氧氧基酶-2选择性非甾体抗炎药（Etodolac，Meloxicam，Celecoxib，Rofecoxib，Etoricoxib，Valdecoxib和Lumiracoxib）用于骨关节炎和类风湿性关节炎：系统审查和经济评估

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号